Nitroxides for use in treating predisposed or at risk patients
Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of diabetes. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl).
1. A method of treatment comprising:
identifying a subject predisposed to or at risk for developing diabetes wherein the subject exhibits no symptoms of diabetes; and
administering to the subject an amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl effective to increase proliferation of pancreatic beta cells, ameliorate insulin resistance, increase intracellular levels of adiponectin or keratinocyte growth factor, or increase expression of an adiponectin or keratinocyte growth factor gene in the subject.
2. The method of claim 1 , wherein the intracellular levels of keratinocyte growth factor are increased.
3. The method of claim 1 , wherein the intracellular levels of adiponectin are increased.
4. The method of claim 1 , wherein the effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is within the range of 0.01-300 mg/kg.
5. The method of claim 1 , wherein the effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is within the range of 0.1-250 mg/kg.
6. The method of claim 1 , wherein the effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is within the range of 1-200 mg/kg.
7. The method of claim 1 , wherein the effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is within the range of 2-150 mg/kg.
8. The method of claim 1 , wherein the effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is within the range of 5-125 mg/kg.
9. The method of claim 1 , wherein the effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is within the range of 7-100 mg/kg.
10. The method of claim 1 , wherein the effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is within the range of 10-75 mg/kg.
11. The method of claim 1 , wherein the effective amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is within the range of 15-30 mg/kg.
12. The method of claim 1 , wherein expression of the keratinocyte growth factor gene is increased.
13. The method of claim 1 , wherein expression of the adiponectin gene is increased.
14. The method of claim 1 , wherein the proliferation of pancreatic beta cells is increased.
15. The method of claim 1 , wherein insulin resistance is ameliorated.
16. The method of claim 1
wherein the subject predisposed to or at risk for developing diabetes has abnormally depressed levels of adiponectin due to abnormally high levels of adipose tissue; and
wherein 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl is an amount effective to increase intracellular levels of adiponectin or increase expression of an adiponectin gene in the subject.
17. The method of claim 1
wherein the subject is obese.
18. A method of treatment comprising:
identifying a subject with abnormally depressed levels of adiponectin due to abnormally high levels of adipose tissue, wherein the subject exhibits no symptoms of diabetes; and
administering to the subject an amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl effective to increase intracellular levels of adiponectin or to increase expression of an adiponectin gene in the subject.
19. The method of claim 18
wherein the subject is obese.
20. A method of treatment comprising:
identifying a subject with abnormally high levels of adipose tissue, wherein the subject exhibits no symptoms of diabetes; and
administering to the subject an amount of 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl effective to increase intracellular levels of adiponectin or to increase expression of an adiponectin gene in the subject.
21. The method of claim 20
wherein the subject is obese.